Human fetal adenohypophysis. Electron microscopic and ultrastructural immunocytochemical analysis

The pituitary glands were removed from 63 human fetuses from 5 weeks of gestation to term and studied by electron microscopy and ultrastructural immunocytochemistry to document the development of cell differentiation and hormone production in the adenohypophysis. At 5 weeks of gestation, Rathke's cleft was lined by columnar epithelium with abundant cytoplasmic glycogen and occasional secretory granules. By 6 weeks of gestation, cells resembling corticotrophs were identified; in 8-week-old fetuses, type I microfilaments were found in those cells. Well-differentiated somatotrophs were seen in adenohypophyses of 8- to 9-week-old fetuses. Although secretory granules were numerous, the Golgi complex was inconspicuous in early fetal glands. After 10 weeks of gestation, there was a change with morphologic evidence of active hormone secretion; large Golgi regions and sparsely granulated cells were found. Some somatotrophs at this stage contained aggregates of type II microfilaments which resembled the fibrous bodies of sparsely granulated somatotroph adenomas. Densely granulated mammosomatotrophs containing growth hormone and prolactin were identified at 12 weeks of gestation. Cells with characteristics of the glycoprotein hormone cell line were seen in pituitaries at 12 weeks of gestation; thyrotrophs and gonadotrophs were identified after 15 weeks. Typical lactotrophs were not recognized before 23 weeks, but were numerous in pituitaries of fetuses older than 35 weeks. This study documents for the first time the existence of a bihormonal mammosomatotroph in the human fetal pituitary and confirms that somatotrophs and lactotrophs, the two acidophil cell types, are embryologically related.(ABSTRACT TRUNCATED AT 250 WORDS)     

Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V

Gln506-factor V (FV) was purified from plasma of an individual homozygous for an Arg506Gln mutation in FV that is associated with activated protein C (APC) resistance. Purified Gln506-FV, as well as Gln506-FVa generated by either thrombin or FXa, conveyed APC resistance to FV-deficient plasma in coagulation assays. Clotting assay studies also suggested that APC resistance does not involve any abnormality in FV-APC-cofactor activity. In purified reaction mixtures, Gln506-FVa in comparison to normal FVa showed reduced susceptibility to APC, because it was inactivated approximately 10-fold slower than normal Arg506-FVa. It was previously reported that inactivation of normal FVa by APC involves an initial cleavage at Arg506 followed by phospholipid- dependent cleavage at Arg306. Immunoblot and amino acid sequence analyses showed that the 102-kD heavy chain of Gln506-FVa was cleaved at Arg306 during inactivation by APC in a phospholipid-dependent reaction. This reduced but measurable susceptibility of Gln506-FVa to APC inactivation may help explain why APC resistance is a mild risk factor for thrombosis because APC can inactivate both normal FVa and variant Gln506-FVa. In summary, this study shows that purified Gln506- FV can account for APC resistance of plasma because Gln506-FVa, whether generated by thrombin or FXa, is relatively resistant to APC.     

Restoration of innate immune activation accelerates Th1‐cell priming and protection following pulmonary mycobacterial infection

The immune mechanisms underlying delayed induction of Th1‐type immunity in the lungs following pulmonary mycobacterial infection remain poorly understood. We have herein investigated the underlying immune mechanisms for such delayed responses and whether a selected innate immune‐modulating strategy can accelerate Th1‐type responses. We have found that, in the early stage of pulmonary infection with attenuated Mycobacterium tuberculosis (M.tb H37Ra), the levels of infection in the lung continue to increase logarithmically until days 14 and 21 postinfection in C57BL/6 mice. The activation of innate immune responses, particularly DCs, in the lung is delayed. This results in a delay in the subsequent downstream immune responses including the migration of antigen‐bearing DCs to the draining lymph node (dLN), the Th1‐cell priming in dLN, and the recruitment of Th1 cells to the lung. However, single lung mucosal exposure to the TLR agonist FimH postinfection is able to accelerate protective Th1‐type immunity via facilitating DC migration to the lung and draining lymph nodes, enhancing DC antigen presentation and Th1‐cell priming. These findings hold implications for the development of immunotherapeutic and vaccination strategies and suggest that enhancement of early innate immune activation is a viable option for improving Th1‐type immunity against pulmonary mycobacterial diseases.